# The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

> **NCT05263570** · — · RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Standard Therapy

## Key facts

- **NCT ID:** NCT05263570
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263570, "The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05263570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*